How do different GLP-1 mimetics differ in their actions?

被引：3

作者：

Choukem S.P.

Gautier J.-F. ^{[1
,2
]}

机构：

[1] Department of Diabetes and Endocrinology, INSERM CIC 9504, Saint-Louis Hospital, 75010 Paris

[2] INSERM U 671, Paris

来源：

Current Diabetes Reports | 2006年 / 6卷 / 5期

关键词：

Metformin; Liraglutide; Insulin Glargine; Exenatide; Vildagliptin;

D O I：

10.1007/s11892-006-0007-x

中图分类号：

学科分类号：

摘要：

Glucagon-like peptide-1 (GLP-1) mimetics have been developed to overcome the pharmacokinetic limitations of GLP-1 for the treatment of type 2 diabetes. Their mechanisms of action and clinical effects appear particularly interesting because they target the main pathophysiologic mechanisms involved in type 2 diabetes. GLP-1 receptor agonists are more powerful and are particularly advantageous by their weight loss-inducing capacity, whereas dipeptidyl peptidase IV inhibitors exhibit a better tolerance profile. However, their ultimate role is still to be defined in the therapeutic strategy of type 2 diabetes. Copyright© 2006 by Current Science Inc.

引用

页码：365 / 372

页数：7

共 63 条

[1]

Standards of medical care in diabetes, Diabetes Care, 29, (2006)

[2]

Overview of 6 years therapy of type II diabetes: A progressive disease, Diabetes, 44, pp. 1249-1258, (1995)

[3]

Moore B., Edie E., Abram J., On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane, Biochem J, 1, pp. 28-38, (1906)

[4]

Creutzfeldt W., The [pre-] history of the incretin concept, Regul Pept, 128, pp. 87-91, (2005)

[5]

Gutniak M., Orskov C., Holst J., Et al., Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus, N Engl J Med, 326, pp. 1316-1322, (1992)

[6]

Bloomgarden Z., Glycemic treatment: Control of glycemia, Diabetes Care, 27, pp. 1227-1234, (2004)

[7]

Holst J., Gromada J., Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans, Am J Physiol Endocrinol Metab, 287, (2004)

[8]

Nauck M., Meier J., Glucagon-like peptide 1 and its derivatives in the treatment of diabetes, Regul Pept, 128, pp. 135-148, (2005)

[9]

Nauck M., Heimesaat M., Orskov C., Et al., Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus, J Clin Invest, 91, pp. 301-307, (1993)

[10]

Zander M., Madsbad S., Madsen J., Holst J., Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and B-cell function in type 2 diabetes: A parallel-group study, Lancet, 359, pp. 824-830, (2002)

← 1 2 3 4 5 6 7 →